Clinical Trial News and Research

RSS

Combination treatment provides effective one-two punch against prostate cancer

Results from a long-term clinical trial conducted by cancer researchers at Houston Methodist Hospital show that combining radiation treatment with "suicide gene therapy," a technique in which prostate cancer cells are genetically modified so they signal a patient's immune system to attack them, provides a safe and effective one-two punch against the disease.

12 Dec 2015

New MSK-led studies on liquid biopsy presented at San Antonio Breast Cancer Symposium

Information gleaned from a liquid biopsy may help predict how individual women with advanced breast cancer will respond to certain therapies as well as reveal genetic mutations that can impact prognosis, according to two new studies led by Memorial Sloan Kettering Cancer Center Physician-in-Chief José Baselga and physician-scientist Sarat Chandarlapaty.

12 Dec 2015

NIAID scientists successfully test prime-boost H7N9 influenza vaccine concept in clinical trial

In clinical trials, several candidate H7N9 pandemic influenza vaccines made from inactivated viruses have been shown to be safe and to generate an immune response. However, scientists believe for practical use, these potential vaccines would require multiple doses or the addition of adjuvants, which enhance the immune response.

12 Dec 2015

FDA approves Vistogard (uridine triacetate) for emergency treatment of chemotherapy overdose

The U.S. Food and Drug Administration today approved Vistogard (uridine triacetate) for the emergency treatment of adults and children who receive an overdose of the cancer treatment fluorouracil or capecitabine, or who develop certain severe or life-threatening toxicities within four days of receiving these cancer treatments.

12 Dec 2015

Anastrozole drug effective in treating early form of breast cancer

The drug anastrozole is effective in treating an early form of breast cancer, according to a clinical trial led by Queen Mary University of London. The results of the IBIS-II DCIS trial show that anastrozole is as effective as tamoxifen for this type of breast cancer and could offer a new treatment option for post-menopausal women.

12 Dec 2015

Early promise for pulmonary artery denervation in PAH patients

Pulmonary artery denervation is feasible and may reduce pulmonary arterial pressure in patients with pulmonary arterial hypertension, phase II findings suggest.

11 Dec 2015

Right atrial function could be prognostic in PAH

Right atrial function is impaired in patients with pulmonary arterial hypertension and may indicate right ventricular overload and failure, research suggests.

11 Dec 2015

Sangamo presents Phase 2 data from two ongoing clinical trials of SB-728-T for treatment of HIV/AIDS

Sangamo BioSciences, Inc., the leader in therapeutic genome editing, announced the presentation of Phase 2 data from two of the Company's ongoing clinical trials (SB-728-1101 Cohort 3* and SB-728-mR-1401) of SB-728-T, which is being developed for the functional control of HIV/AIDS.

11 Dec 2015

Adjuvant chemotherapy not beneficial for patients with luminal A subtype of breast cancer

Premenopausal women whose invasive breast cancers were of the luminal A subtype had comparable 10-year disease-free survival rates regardless of whether or not they received adjuvant chemotherapy, according to data from the phase III DBCG77B clinical trial presented at the 2015 San Antonio Breast Cancer Symposium, held Dec. 8-12.

11 Dec 2015

Pathologic complete response after presurgery chemotherapy increases overall survival for TNBC patients

Patients with stage 2 or stage 3 triple-negative breast cancer (TNBC) who had a pathologic complete response (pCR) after presurgery chemotherapy had increased event-free and overall survival compared with those who had more than minimal residual invasive disease at surgery following presurgery chemotherapy, according to results from the randomized phase II CALGB/Alliance 40603 clinical trial presented at the 2015 San Antonio Breast Cancer Symposium, held Dec. 8-12.

11 Dec 2015

Capecitabine increases disease-free survival for HER2-negative breast cancer patients

Treatment with the chemotherapy agent capecitabine increased disease-free survival for women with HER2-negative breast cancer that was not eliminated by presurgery chemotherapy, according to results from the phase III CREATE-X clinical trial presented at the 2015 San Antonio Breast Cancer Symposium, held Dec. 8-12.

11 Dec 2015

UB physicians testing new exercise treatment for concussion

The standard of care for acute concussion may undergo a dramatic change, depending on the results of a new exercise treatment that physicians at the Jacobs School of Medicine and Biomedical Sciences at the University at Buffalo have developed and begun testing. It is the first randomized, controlled clinical trial of this exercise treatment for concussion.

11 Dec 2015

Videregen-led TETRA consortium awarded EUR 6.8 million for pivotal Phase II trial of replacement trachea

The pan-European TETRA consortium, led by Videregen Limited, has been awarded EUR 6.8 million under the Horizon 2020 programme for a pivotal Phase II clinical trial of the company's tissue engineered replacement trachea.

10 Dec 2015

NeuroQuest to start U.S. clinical validation trials of blood test for early diagnosis of Alzheimer's disease

NeuroQuest Development Center, Inc., today announced they have entered into a service agreement with the University of California, San Diego for collection and processing of blood samples for their U.S. clinical validation trials.

10 Dec 2015

Palatin achieves patient enrollment target in pivotal phase 3 studies of bremelanotide for FSD treatment

Palatin Technologies, Inc., a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical needs and commercial potential, today announced it has achieved its patient enrollment target in its two pivotal phase 3 clinical studies of bremelanotide for the treatment of female sexual dysfunction (FSD).

10 Dec 2015

Lilly, Merck announce another immuno-oncology collaboration

Eli Lilly and Company and Merck, known as MSD outside the United States and Canada, today announced another immuno-oncology collaboration that will evaluate abemaciclib (LY2835219), Lilly's cyclin-dependent kinase (CDK) 4 and 6 inhibitor, and Merck's KEYTRUDA (pembrolizumab) in a Phase I study across multiple tumor types.

10 Dec 2015

New heart failure drug may increase patients' risk of Alzheimer's disease, macular degeneration

Patients with mild heart failure stand to benefit from a new drug that can halt the progression of their disease and reduce their risk of cardiovascular-related death. But the drug -- a tablet that combines the agents valsartan and sacubitril, sold under the trade name Entresto by drugmaker Novartis -- may be too good to be true, according to Arthur M. Feldman, MD, PhD, Executive Dean of the Lewis Katz School of Medicine at Temple University, Chief Academic Officer of the Temple University Health System, and Laura H. Carnell Professor of Medicine at LKSOM.

10 Dec 2015

Clinical Trial News and Research

Combination treatment provides effective one-two punch against prostate cancer

New MSK-led studies on liquid biopsy presented at San Antonio Breast Cancer Symposium

NIAID scientists successfully test prime-boost H7N9 influenza vaccine concept in clinical trial

FDA approves Vistogard (uridine triacetate) for emergency treatment of chemotherapy overdose

Anastrozole drug effective in treating early form of breast cancer

Early promise for pulmonary artery denervation in PAH patients

Right atrial function could be prognostic in PAH

Sangamo presents Phase 2 data from two ongoing clinical trials of SB-728-T for treatment of HIV/AIDS

Adjuvant chemotherapy not beneficial for patients with luminal A subtype of breast cancer

Pathologic complete response after presurgery chemotherapy increases overall survival for TNBC patients

Capecitabine increases disease-free survival for HER2-negative breast cancer patients

UB physicians testing new exercise treatment for concussion

Videregen-led TETRA consortium awarded EUR 6.8 million for pivotal Phase II trial of replacement trachea

NeuroQuest to start U.S. clinical validation trials of blood test for early diagnosis of Alzheimer's disease

Palatin achieves patient enrollment target in pivotal phase 3 studies of bremelanotide for FSD treatment

Lilly, Merck announce another immuno-oncology collaboration

New heart failure drug may increase patients' risk of Alzheimer's disease, macular degeneration

Sinovac gets approval to begin clinical trials on Sabin Inactivated Polio Vaccine candidate

Boehringer Ingelheim begins SENSCIS study to investigate safety, efficacy of nintedanib in patients with SSc-ILD

VNS technology could help improve lives of people recovering from stroke

eBook: Using iPSCs models for human disease research and drug discovery eBook

Latest eBooks

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Advancing degrader and proximity-based drug development

Driving innovation in Korean drug development

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Applications Engineer